SphingoTec to Present New penKid Sepsis Data and Co-Host Sepsis Symposium at ESICM Lives 2026
核心洞察
SphingoTec will co-host a Scientific Symposium with partner Boditech (搜索) at ESICM Lives 2026 (October 10–14, Lisbon), focusing on innovations in sepsis (搜索) diagnostics.
New clinical data on penKid from a multicenter sepsis (搜索) study will be presented as a poster at the ESICM congress.
At ASN Kidney Week 2026 (October 22–25, Denver), penKid will feature in a poster titled "Proenkephalin Predicts Severe AKI in High-Risk Patients."
SphingoTec GmbH, a Hennigsdorf, Germany-based biomarker company, will present new clinical data on its Proenkephalin A 119-159 (penKid) (搜索) biomarker and co-host a scientific symposium on sepsis (搜索) diagnostics at ESICM Lives 2026, taking place October 10–14, 2026, in Lisbon, Portugal. The company announced its conference schedule on August 19, 2026, outlining a series of engagements across diagnostics and critical care medicine over the coming months.
At ESICM Lives, SphingoTec will co-host a Scientific Symposium together with business partner Boditech (搜索), focusing on innovations in sepsis (搜索) diagnostics. In parallel, new clinical data on penKid from a multicenter sepsis study will be presented as a poster at the ESICM congress.
penKid Data Across Major Nephrology and Critical Care Conferences
SphingoTec's penKid biomarker will take center stage at ASN Kidney Week 2026, scheduled for October 22–25, 2026, in Denver, Colorado. The company will present the abstract "Proenkephalin Predicts Severe AKI in High-Risk Patients" in the poster sessions, underscoring penKid's role in assessing kidney function in critical diseases.
The company's broader conference schedule also includes the Kongress für Nephrologie 2026 (DGFN / Deutsche Gesellschaft für Nephrologie), October 8–11, 2026, in Leipzig, Germany, as well as DGAI (Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin), September 16–18, 2026, in Kassel, Germany.
Expanding the Biomarker Portfolio in Critical Care
SphingoTec's proprietary biomarker portfolio includes penKid, a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM) (搜索), a biomarker for the assessment of endothelial function in conditions such as sepsis (搜索) and acute heart failure (搜索).
"These events bring together clinicians, researchers, and industry partners who share our goal of improving outcomes for patients in critical care," said Deborah Bergmann, CEO of SphingoTec. "By presenting our latest data and engaging in direct dialogue, we aim to strengthen collaborations that translate biomarker innovation into real clinical value."
Commercial and Partnering Strategy
SphingoTec focuses on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. The company develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms.
At Medica, November 16–19, 2026, in Düsseldorf, Germany, SphingoTec will focus on expanding its international industry network and advancing partnering opportunities for its biomarker portfolio. The company will also attend DIVI (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin), December 2–4, 2026, in Hamburg, Germany.
Earlier in the year, SphingoTec announced that CEO Deborah Bergmann would attend the ADLM 2026 Annual Meeting, July 26–30, 2026, to engage with current and prospective partners on advancing innovations in critical care diagnostics. "ADLM provides an important platform to connect with partners across the diagnostics ecosystem," Bergmann said. "These discussions align with our commitment to translating biomarker innovation into clinically meaningful solutions for patients in critical care."